Thomas Pietschmann

5.3k total citations · 2 hit papers
112 papers, 3.5k citations indexed

About

Thomas Pietschmann is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Thomas Pietschmann has authored 112 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Hepatology, 65 papers in Epidemiology and 19 papers in Infectious Diseases. Recurrent topics in Thomas Pietschmann's work include Hepatitis C virus research (71 papers), Hepatitis B Virus Studies (39 papers) and Liver Disease Diagnosis and Treatment (23 papers). Thomas Pietschmann is often cited by papers focused on Hepatitis C virus research (71 papers), Hepatitis B Virus Studies (39 papers) and Liver Disease Diagnosis and Treatment (23 papers). Thomas Pietschmann collaborates with scholars based in Germany, France and United States. Thomas Pietschmann's co-authors include Eike Steinmann, Gabrielle Vièyres, Jan Buer, Jörg Steinmann, Richard J. P. Brown, Ralf Bartenschlager, Stephanie Pfaender, Gisa Gerold, Florian W. R. Vondran and Lars Kaderali and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Angewandte Chemie International Edition.

In The Last Decade

Thomas Pietschmann

109 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti‐infective properties of epigallocatechin‐3‐gallate (EGCG), a component of green tea

2012 447 citations Thomas Pietschmann, Eike Steinmann et al. profile →
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies

2018 131 citations Thomas F. Baumert, Thomas Pietschmann et al. Virus Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Pietschmann Germany	32	1.6k	1.4k	704	683	449	112	3.5k
Philip Meuleman Belgium	43	3.5k 2.2×	2.7k 2.0×	766 1.1×	823 1.2×	555 1.2×	121	5.4k
Gilles Duverlie France	33	2.6k 1.7×	2.1k 1.6×	541 0.8×	786 1.2×	333 0.7×	111	4.0k
Ishtiaq Qadri Saudi Arabia	35	914 0.6×	1.6k 1.2×	1.2k 1.7×	384 0.6×	358 0.8×	138	3.8k
Yoshio Mori Japan	30	823 0.5×	788 0.6×	816 1.2×	1.2k 1.8×	294 0.7×	176	3.5k
Hak Hotta Japan	44	2.6k 1.6×	2.9k 2.1×	1.9k 2.7×	805 1.2×	1.1k 2.5×	229	6.4k
Mirjam B. Zeisel France	41	3.0k 1.9×	2.8k 2.1×	1.3k 1.8×	366 0.5×	682 1.5×	92	5.1k
Junqi Niu China	40	2.5k 1.6×	2.9k 2.2×	1.5k 2.1×	699 1.0×	993 2.2×	267	5.7k
Hideyuki Ikematsu Japan	36	604 0.4×	1.9k 1.4×	524 0.7×	549 0.8×	1.4k 3.1×	194	4.1k
Robert T. Sarisky United States	33	533 0.3×	1.5k 1.1×	645 0.9×	561 0.8×	811 1.8×	65	3.0k
Koichi Watashi Japan	43	3.8k 2.4×	4.2k 3.1×	2.5k 3.5×	1.2k 1.7×	1.1k 2.4×	192	7.7k

Countries citing papers authored by Thomas Pietschmann

Since Specialization

Citations

This map shows the geographic impact of Thomas Pietschmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Pietschmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Pietschmann more than expected).

Fields of papers citing papers by Thomas Pietschmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Pietschmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Pietschmann. The network helps show where Thomas Pietschmann may publish in the future.

Co-authorship network of co-authors of Thomas Pietschmann

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Pietschmann. A scholar is included among the top collaborators of Thomas Pietschmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Pietschmann. Thomas Pietschmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jumde, Ravindra P., Margarida Saramago, Sebastian Adam, et al.. (2024). Dynamic Combinatorial Chemistry Unveils Nsp10 Inhibitors with Antiviral Potential Against SARS‐CoV‐2. Chemistry - A European Journal. 31(4). e202403390–e202403390. 1 indexed citations

Vièyres, Gabrielle & Thomas Pietschmann. (2023). The role of human lipoproteins for hepatitis C virus persistence. Current Opinion in Virology. 60. 101327–101327.

Vondran, Florian W. R., et al.. (2023). Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell‐derived hepatocytes. Liver International. 43(10). 2116–2129. 5 indexed citations

Keller, Lena, Emilia Oueis, Susanne H. Kirsch, et al.. (2022). Persicamidines—Unprecedented Sesquarterpenoids with Potent Antiviral Bioactivity against Coronaviruses. Angewandte Chemie International Edition. 62(6). e202214595–e202214595. 10 indexed citations

Ham, Marco van, Miriam Becker, Graham Brogden, et al.. (2021). Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. iScience. 24(12). 103469–103469. 17 indexed citations

Risso-Ballester, Jennifer, Marie Galloux, Jingjing Cao, et al.. (2021). A condensate-hardening drug blocks RSV replication in vivo. Nature. 595(7868). 596–599. 146 indexed citations

Carpentier, Arnaud, Julie Sheldon, Florian W. R. Vondran, Richard J. P. Brown, & Thomas Pietschmann. (2020). Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus. Gut. 69(9). 1659–1666. 15 indexed citations

Kinast, Volker, Richard J. P. Brown, Gabrielle Vièyres, et al.. (2019). Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. Cells. 8(6). 610–610. 6 indexed citations

Bruening, Janina, Carine Marinach, Florian W. R. Vondran, et al.. (2018). Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB. PLoS Pathogens. 14(7). e1007111–e1007111. 43 indexed citations

10.

Frich, Camilla Kaas, Kaja Zuwała, Frederik Dagnæs‐Hansen, et al.. (2017). Synthetic Polymer with a Structure-Driven Hepatic Deposition and Curative Pharmacological Activity in Hepatic Cells. ACS Macro Letters. 6(9). 935–940. 2 indexed citations

11.

Xu, Shuting, Aurélie Ducroux, Gabrielle Vièyres, et al.. (2016). cGAS-Mediated Innate Immunity Spreads Intercellularly through HIV-1 Env-Induced Membrane Fusion Sites. Cell Host & Microbe. 20(4). 443–457. 41 indexed citations

12.

Anggakusuma, Richard J. P. Brown, Dominic H. Banda, et al.. (2016). Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission. Journal of Virology. 90(23). 10670–10681. 27 indexed citations

13.

Lauber, Chris, Gabrielle Vièyres, Ewa Terczyńska‐Dyla, et al.. (2015). Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells. Genes and Immunity. 16(6). 414–421. 39 indexed citations

14.

Vercauteren, Koen, Richard J. P. Brown, Ahmed Atef Mesalam, et al.. (2015). Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. Gut. 65(12). 2029–2034. 22 indexed citations

15.

Gerold, Gisa, Janina Bruening, & Thomas Pietschmann. (2015). Decoding protein networks during virus entry by quantitative proteomics. Virus Research. 218. 25–39. 22 indexed citations

16.

Grabski, Elena, Ilka Wappler, Stephanie Pfaender, et al.. (2015). Efficient Virus Assembly, but Not Infectivity, Determines the Magnitude of Hepatitis C Virus-Induced Interferon Alpha Responses of Plasmacytoid Dendritic Cells. Journal of Virology. 89(6). 3200–3208. 6 indexed citations

17.

Pfaender, Stephanie, Daniel Tödt, Joerg Steinmann, et al.. (2014). Mechanisms of Methods for Hepatitis C Virus Inactivation. Applied and Environmental Microbiology. 81(5). 1616–1621. 44 indexed citations

18.

Fiedler, Melanie, Dorothea Bankwitz, William O. Osburn, et al.. (2014). Hepatitis C Virus Hypervariable Region 1 Variants Presented on Hepatitis B Virus Capsid-Like Particles Induce Cross-Neutralizing Antibodies. PLoS ONE. 9(7). e102235–e102235. 7 indexed citations

19.

Pietschmann, Thomas. (2013). A century of international drug control. PubMed. 59(1-2). 1–2. 14 indexed citations

20.

Mederacke, Ingmar, Sandra Ciesek, R. Raupach, et al.. (2009). 333 KINETICS OF HCV CORE ANTIGEN DURING ANTIVIRAL TREATMENT OF ACUTE AND CHRONIC HEPATITIS C AS DETERMINED BY A NOVEL CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY. Journal of Hepatology. 50. S129–S129. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact